Get notified when IMUX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- There Is No Public Trading Market For the Warrants Being Offered In This Offering, and We Do Not Expect a Market to Develop. (new) — The warrants are unlisted and illiquid, which may trap investors who cannot sell them.
- We Will Need to Raise Additional Capital Through Public or Private Equity or Debt Offerings or Through Arrangements With Strategic Partners or Other Sources In Order to Continue to Develop Our Drug Candidates. (new) — The company explicitly states it will need further capital, indicating ongoing funding risk.
Immunic prices $65M primary offering of pre-funded warrants and Series A/B warrants at $0.75 per share
Filed May 30, 2025 · ~1 min read
Key Changes
-
high
Immunic is offering pre-funded warrants to buy 86,666,667 shares, each paired with Series A and B warrants, at $0.7499 per unit. The company receives all proceeds.
The Offering verify on EDGAR → -
high
Net proceeds to the company are approximately $60.6 million after underwriting discounts and expenses, excluding any warrant exercise proceeds.
Use of Proceeds verify on EDGAR → -
medium
Proceeds will fund clinical trials, operations, and general corporate purposes. The company has never paid dividends and does not expect to.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade IMUX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify